| A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults (NCT00000853) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients (NCT00001102) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines (NCT00002402) | VaxGen | |
| Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients (NCT00002012) | Interferon Sciences | |
| A Comparison of Two Tests for Anti-HIV Drug Resistance (NCT00006490) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Dideoxycytidine in HIV-Infected Patients (NCT00000997) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection (NCT00002183) | Glaxo Wellcome | |
| Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir® (NCT00622141) | The HIV Netherlands Australia Thailand Research Collaboration | |
| The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT (NCT00002436) | Glaxo Wellcome | |
| Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 (NCT00000891) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects (NCT00000845) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma (NCT00000681) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of T-20 in HIV-Positive Adults (NCT00002228) | Trimeris | |
| A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers (NCT00001992) | Genentech, Inc. | |
| A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia (NCT00002258) | Sandoz | |
| Prevalence of Hepatitis C Virus Infection in HIV-Infected Children (NCT00037076) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir (NCT00002310) | Shaman Pharmaceuticals | |
| A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients (NCT00000824) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants (NCT00038480) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients (NCT00002230) | Northwestern University | |
| A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations (NCT00002430) | Merck Sharp & Dohme LLC | |
| Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients (NCT00046267) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine (NCT00001136) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Acceptability of a Vaginal Microbicide (NCT00111943) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Growth Hormone Treatment of Children With HIV-Associated Growth Failure (NCT00006143) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) (NCT00002125) | Astra USA | |
| A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients (NCT00000890) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine (NCT00000828) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis (NCT00002187) | Ionis Pharmaceuticals, Inc. | |
| A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine (NCT00002333) | Hoffmann-La Roche | |
| A Study of Lobucavir in Patients With AIDS (NCT00002352) | Bristol-Myers Squibb | |
| A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients (NCT00000748) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients (NCT00002050) | Immunobiology Research Institute | |
| A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients (NCT00002151) | Hoechst Marion Roussel | |
| A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects. (NCT00002199) | Glaxo Wellcome | |
| The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients (NCT00002404) | Glaxo Wellcome | |
| Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy (NCT00107549) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children (NCT00000773) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs (NCT00001083) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients (NCT00002128) | Gilead Sciences | |
| A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS (NCT00000992) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa (NCT00304668) | International Partnership for Microbicides, Inc. | |
| An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients (NCT00002266) | Wyeth is now a wholly owned subsidiary of Pfizer | |
| A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women (NCT00000864) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies (NCT00001016) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children (NCT00000913) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection (NCT00000702) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity (NCT00000977) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection (NCT00000636) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals (NCT00272493) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV (NCT00051090) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers (NCT00001090) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3 (NCT00000712) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection (NCT00000984) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers (NCT00001055) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease (NCT00002081) | Hoffmann-La Roche | |
| Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain (NCT00082316) | NeurogesX | |
| Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease (NCT00000626) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers (NCT00002059) | Newport Pharmaceuticals International | |
| A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone (NCT00000788) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160 (NCT00000956) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis (NCT00002158) | Romark Laboratories L.C. | |
| The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients (NCT00002346) | Gilead Sciences | |
| A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma (NCT00000954) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN) (NCT00000819) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission (NCT00021671) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications (NCT01909414) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin (NCT00001989) | Genelabs Technologies | |
| A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea (NCT00001018) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2 (NCT00002023) | Glaxo Wellcome | |
| A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs (NCT00002369) | Bristol-Myers Squibb | |
| A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn) (NCT00000631) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission (NCT00053612) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Changing to Nonprotease Inhibitor Treatment to Improve Side Effects (NCT00021463) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection (NCT00000793) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis (NCT00002321) | Chiron Corporation | |
| The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma (NCT00001114) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy (NCT00061152) | NeurogesX | |
| Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects (NCT00000740) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults (NCT00054860) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA) (NCT00000886) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection (NCT00000872) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3 (NCT00000857) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs (NCT00002407) | Weill Medical College of Cornell University | |
| Heterosexual HIV Transmission Study (HATS). Prospective Cohort Study (NCT00000787) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex (NCT00001011) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication (NCT00006578) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma (NCT00000725) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects (NCT00000713) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load. (NCT00040157) | Alexion Pharmaceuticals, Inc. | |
| A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) (NCT00000781) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC (NCT00002020) | Glaxo Wellcome | |
| The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients (NCT00000962) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas (NCT00002003) | Lederle Laboratories | |
| A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients (NCT00002195) | Glaxo Wellcome | |
| Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children (NCT00000901) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection (NCT00002249) | R W Johnson Pharmaceutical Research Institute | |
| A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma (NCT00002348) | Genzyme, a Sanofi Company | |
| A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection. (NCT00002097) | Argus Pharmaceuticals | |
| A Study of Two Anti-HIV Drug Combinations (NCT00002203) | Glaxo Wellcome | |